NASDAQ:STRO
Sutro Biopharma, Inc.
Sutro Biopharma, Inc.'s revenue grew 65.2% in fiscal 2025 to $102.5M while operating margin rose to −154.5%. The diluted share count rose 9.8%.Summary generated from Sutro Biopharma, Inc.'s SEC filings. Latest annual report filed Mar 23, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$102.5M
Revenue growth+65.2%
Revenue, 5-yr CAGR+19.1%
Gross marginn/a
Operating margin−154.5%
Net margin−186.5%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+9.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 62 | 68 | 154 | 62 | 102 |
| Operating income | −99 | −129 | −89 | −238 | −158 |
| Net income | −106 | −119 | −107 | −227 | −191 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Sep 22, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 4Insider transaction report
Jun 9, 2026 - 8-KResults of a shareholder vote
Jun 8, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 14, 2026 - 8-KResults of operations and financial condition
May 14, 2026 - DEF 14AProxy statement
Apr 22, 2026